Literature DB >> 10879793

Human IL-2 receptor alpha chain deficiency.

C M Roifman1.   

Abstract

Profound cellular immunodeficiency occurs as the result of mutations in proteins involved in both the differentiation and function of mature lymphoid cells. We describe here a novel human immune aberration arising from a truncation mutation of the IL-2 receptor alpha chain (CD25), a subunit of the tripartite high-affinity receptor for IL-2. Decreased numbers of peripheral T cells displaying abnormal proliferation but normal B-cell development characterize this immunodeficiency. Extensive lymphocytic infiltration of tissues, including lung, liver, gut, and bone, is observed, accompanied by tissue atrophy and inflammation. Although mature T cells are present, the absence of CD25 does affect the differentiation of thymocytes. Although displaying normal development of CD2, CD3, CD4, and CD8 expression, CD25-deficient cortical thymocytes do not express CD1. Furthermore, they fail to down-regulate levels of bcl-2 and, subsequently, apoptosis in the thymus is markedly reduced, resulting in expansion of autoreactive clones in multiple tissues.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10879793     DOI: 10.1203/00006450-200007000-00004

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  41 in total

Review 1.  Therapeutic targeting of Janus kinases.

Authors:  Marko Pesu; Arian Laurence; Nandini Kishore; Samuel H Zwillich; Gary Chan; John J O'Shea
Journal:  Immunol Rev       Date:  2008-06       Impact factor: 12.988

2.  CD4(+)CD25(+)Foxp3(+) regulatory T cells promote Th17 cells in vitro and enhance host resistance in mouse Candida albicans Th17 cell infection model.

Authors:  Pushpa Pandiyan; Heather R Conti; Lixin Zheng; Alanna C Peterson; Douglas R Mathern; Nydiaris Hernández-Santos; Mira Edgerton; Sarah L Gaffen; Michael J Lenardo
Journal:  Immunity       Date:  2011-03-25       Impact factor: 31.745

3.  Genetic disorders with immune dysregulation.

Authors:  Eleonora Gambineri; Troy R Torgerson
Journal:  Cell Mol Life Sci       Date:  2011-10-09       Impact factor: 9.261

Review 4.  Anti-Tac (daclizumab, Zenapax) in the treatment of leukemia, autoimmune diseases, and in the prevention of allograft rejection: a 25-year personal odyssey.

Authors:  Thomas A Waldmann
Journal:  J Clin Immunol       Date:  2007-01-11       Impact factor: 8.317

5.  Novel CD28-responsive enhancer activated by CREB/ATF and AP-1 families in the human interleukin-2 receptor alpha-chain locus.

Authors:  J H Yeh; P Lecine; J A Nunes; S Spicuglia; P Ferrier; D Olive; J Imbert
Journal:  Mol Cell Biol       Date:  2001-07       Impact factor: 4.272

Review 6.  Cytokine Signaling in the Development and Homeostasis of Regulatory T cells.

Authors:  Kevin H Toomer; Thomas R Malek
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-03-01       Impact factor: 10.005

Review 7.  Regulatory T Cells: the Many Faces of Foxp3.

Authors:  Peter Georgiev; Louis-Marie Charbonnier; Talal A Chatila
Journal:  J Clin Immunol       Date:  2019-09-02       Impact factor: 8.317

Review 8.  Beyond regulatory T cells: the potential role for IL-2 to deplete T-follicular helper cells and treat autoimmune diseases.

Authors:  André Ballesteros-Tato
Journal:  Immunotherapy       Date:  2014       Impact factor: 4.196

9.  IL-2 as a therapeutic target for the restoration of Foxp3+ regulatory T cell function in organ-specific autoimmunity: implications in pathophysiology and translation to human disease.

Authors:  Eva d'Hennezel; Mara Kornete; Ciriaco A Piccirillo
Journal:  J Transl Med       Date:  2010-11-08       Impact factor: 5.531

Review 10.  Regulatory T cells in asthma.

Authors:  Clare M Lloyd; Catherine M Hawrylowicz
Journal:  Immunity       Date:  2009-09-18       Impact factor: 31.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.